Insider Purchases: Inside the Buy
Tag: CEO Conviction
Western Union (WU): Cash Transfers, CEO Buys, and Maybe a Stock Rebound?
💸 Western Union’s CEO and CFO just wired big money into their own stock. Institutions already hold 95% of the float, but growth is flat, competition is fierce, and risks abound. Is this a bargain play — or a value trap in disguise?
Bakkt Holdings CEO Buys Shares; Are Profits Baked In?
Bakkt (BKKT) is back on the radar. With a new CEO buying $1.47M of stock and losses shrinking fast, is this crypto play baked to perfection—or half-baked hype?
Can Olin Cock Its Stock? Insiders Say Yes (Lock, Load, and Maybe Profit)
Olin ($OLN) insiders are loading up on shares while institutions already own 94% of the float. Profits are weak, ammo is hot, and bleach is… bleach. Can this 132-year-old company cock its stock for a rebound?
iHeartMedia (IHRT): Turning the Volume Back Up?
Insiders are piling in, institutions are holding strong, and iHeartMedia is betting big on podcasts to fuel its turnaround. But with heavy debt and radio stagnation, is IHRT a hidden gem or just background noise?
Amrize Will Rise, Insiders Undoubtedly Think
Amrize insiders are loading up on stock like it’s on sale at Home Depot. With infrastructure and housing tailwinds, it’s tempting — but watch out for valuation cracks.
Eastman Kodak (KODK): Insider Buys, Debt Drama & a Pivot to Pills?!
Eastman Kodak insiders are snapping up shares, with CEO Jim Continenza leading the charge. But Kodak’s finances are shaky, its debt heavy, and its pivot to pharmaceuticals uncertain. High risk, high reward — or just a faded picture?
MaxCyte (MXCT) — Insiders Load Up While Cash Burns
MaxCyte insiders are shopping biotech shares like it’s Black Friday 🛒💉. With revenue slipping, cash burning, but institutions holding, is MXCT a comeback spark ⚡ or a treadmill burn-out 🔥?
Insiders Are Buying Shares of Applied Optoelectronics. Should You?
Applied Optoelectronics (AAOI) insiders—including the CEO—are buying big while revenue growth accelerates and losses shrink. Institutions already own two-thirds of the stock. But with dilution risk, short sellers circling, and heavy competition, is AAOI a comeback kid—or just another speculative fiber bet?
Financials Paint a Dire Story… But Tronox’s CEO and Insiders See Light in the TiO₂ Pigment
Tronox isn’t just about titanium dioxide anymore—it’s about insider confidence, global reach, and whether this chemical giant’s bright white future is worth your green 💵. From insider purchases to institutional moves, here’s why investors might want to watch TROX closely.
Elite Buys Ely: Should You Buy Lilly’s Stock Too?
Eli Lilly insiders are opening their wallets after the company crushed Q2 2025 — revenue up 38%, EPS up 92%, and blockbuster drugs Zepbound and Mounjaro fueling a raised guidance. Institutions are all-in, the pipeline is buzzing, but the valuation is sky-high. Is LLY worth chasing at $639, or is patience the better prescription?